Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0VZDWP
ADC Name
Anti-BCMA 15B2WT-SG3249
Synonyms
Anti-BCMA-15B2WT SG3249
   Click to Show/Hide
Organization
MedImmune LLC
Drug Status
Investigative
Indication
In total 2 Indication(s)
Multiple myeloma [ICD11:2A83]
Investigative
Plasma cell myeloma [ICD11: 2A83]
Investigative
Drug-to-Antibody Ratio
1.82
Antibody Name
Anti-BCMA antibody 15B2WT
  Antibody Info 
Antigen Name
Tumor necrosis factor receptor superfamily member 17 (TNFRSF17)
  Antigen Info 
Payload Name
SG3199
  Payload Info 
Therapeutic Target
Human Deoxyribonucleic acid (hDNA)
  Target Info 
Linker Name
CL2A
  Linker Info 
Conjugate Type
Random conjugation through reduced inter-chain cysteines.
Combination Type
SG3249
General Information of The Activity Data Related to This ADC
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Tumor Growth Inhibition value (TGI) 
≈ 95.59
%
CVCL_1600
Plasma cell myeloma
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 95.59% (Day 21) High BCMA expression (BCMA+++)
Method Description
Mice were treated with either a single intravenous dose of the ADCs at 0.3 mg/kg or dosed intravenously with J6M0-mc-MMAFweekly at a dose of 0.3 mg/kg for 2 weeks.
In Vivo Model NCI-H929 CDX model
In Vitro Model Plasma cell myeloma NCI-H929 cells CVCL_1600
References
Ref 1 Bcma monoclonal antibody-drug conjugate.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.